EP2091334A4 - INJECTION THERAPY IN TUMORS OF DENDRITIC CELLS AND VACCINE THEREOF - Google Patents

INJECTION THERAPY IN TUMORS OF DENDRITIC CELLS AND VACCINE THEREOF

Info

Publication number
EP2091334A4
EP2091334A4 EP07871309A EP07871309A EP2091334A4 EP 2091334 A4 EP2091334 A4 EP 2091334A4 EP 07871309 A EP07871309 A EP 07871309A EP 07871309 A EP07871309 A EP 07871309A EP 2091334 A4 EP2091334 A4 EP 2091334A4
Authority
EP
European Patent Office
Prior art keywords
vaccine
tumors
dendritic cells
injection therapy
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07871309A
Other languages
German (de)
French (fr)
Other versions
EP2091334A2 (en
Inventor
Kenichiro Hasumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hasumi International Res Foundation
Original Assignee
Hasumi International Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hasumi International Res Foundation filed Critical Hasumi International Res Foundation
Publication of EP2091334A2 publication Critical patent/EP2091334A2/en
Publication of EP2091334A4 publication Critical patent/EP2091334A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP07871309A 2006-10-31 2007-10-31 INJECTION THERAPY IN TUMORS OF DENDRITIC CELLS AND VACCINE THEREOF Withdrawn EP2091334A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85590506P 2006-10-31 2006-10-31
PCT/US2007/083161 WO2008063837A2 (en) 2006-10-31 2007-10-31 Dendritic cell tumor injection therapy and related vaccine

Publications (2)

Publication Number Publication Date
EP2091334A2 EP2091334A2 (en) 2009-08-26
EP2091334A4 true EP2091334A4 (en) 2010-02-03

Family

ID=39430435

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07871309A Withdrawn EP2091334A4 (en) 2006-10-31 2007-10-31 INJECTION THERAPY IN TUMORS OF DENDRITIC CELLS AND VACCINE THEREOF

Country Status (3)

Country Link
EP (1) EP2091334A4 (en)
JP (1) JP2010508364A (en)
WO (1) WO2008063837A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120128656A1 (en) * 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
US8961957B2 (en) * 2012-06-27 2015-02-24 Hasumi International Research Foundation Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
KR20260036555A (en) * 2023-07-05 2026-03-17 이뮤니티바이오, 인크. In vitro generation of immune effector cells from intermediates of collected substances

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082806A1 (en) * 2001-04-27 2003-05-01 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated T cells
US7745157B2 (en) * 2003-02-21 2010-06-29 University Of Maryland, Baltimore Human lymphocyte medium adjuvant
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
HATFIELD P ET AL: "Radiation-induced cell death and dendritic cells: potential for cancer immunotherapy?", CLINICAL ONCOLOGY, W.B. SAUNDERS, vol. 17, no. 1, 1 February 2005 (2005-02-01), pages 1 - 11, XP004693844, ISSN: 0936-6555 *
KATANO MITSUO ET AL: "Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 25, no. 6A, 1 November 2005 (2005-11-01), pages 3771 - 3776, XP009127019, ISSN: 0250-7005 *
MANN DEAN L ET AL: "Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES SEP 2009, vol. 1174, September 2009 (2009-09-01), pages 41 - 50, XP002559589, ISSN: 1749-6632 *
MORISAKI T ET AL: "COMBINED IMMUNOTHERAPY WITH INTRACAVITAL INJECTION OF ACTIVATED LYMPHOCYTES, MONOCYTE-DERIVED DENDRITIC CELLS AND LOW-DOSE OK-432 IN PATIENTS WITH MALIGNANT EFFUSION", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 23, no. 6A, 1 November 2003 (2003-11-01), pages 4459 - 4466, XP009063436, ISSN: 0250-7005 *
MORISAKI TAKASHI ET AL: "Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.", HUMAN CELL : OFFICIAL JOURNAL OF HUMAN CELL RESEARCH SOCIETY DEC 2003, vol. 16, no. 4, December 2003 (2003-12-01), pages 175 - 182, XP009063515, ISSN: 0914-7470 *
SATO TAKAMI ET AL: "Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: A new approach to cancer immunotherapy.", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 53, no. 1, January 2004 (2004-01-01), pages 53 - 61, XP002560230, ISSN: 0340-7004 *
YANO YUTARO ET AL: "A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: Efficient maturation of DCs by co-culture with LAK cells in vitro", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, vol. 16, no. 1, 1 July 2006 (2006-07-01), pages 147 - 152, XP009127013 *
YU BIN ET AL: "Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 1, 1 January 2003 (2003-01-01), pages 285 - 294, XP002425821, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
EP2091334A2 (en) 2009-08-26
WO2008063837A3 (en) 2008-09-18
JP2010508364A (en) 2010-03-18
WO2008063837A9 (en) 2008-08-07
WO2008063837A2 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
IL294095A (en) Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
EP2203470A4 (en) VACCINES AND VACCINE COMPONENTS FOR INHIBITING MICROBIAL CELLS
EP2367425A4 (en) COMBINATIONS AND METHODS OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATORY THERAPY
IL274309B (en) Therapeutic nuclease preparations and methods
EP2061504A4 (en) COMBINATORY THERAPY AGAINST CANCER AND INFECTIOUS DISEASES USING VACCINE AND ANTI-B7-H1
EP2244720A4 (en) POLYPEPTIDE VACCINE AND VACCINATION STRATEGY AGAINST MYCOBACTERIA
EP2115002A4 (en) TARGETED ANTIGEN VACCINES WITH DCIR EXPRESSED IN CELLS HAVING ANTIGEN
EP2084267A4 (en) VACCINES COMPRISING ANTIGENS OF CANCER STEM CELLS AND METHODS
DK2231123T3 (en) Methods and compositions for oral administration of protein and peptide therapy agents
EP2279253A4 (en) PREPARATION AND ADMINISTRATION OF THERAPEUTIC COMPOSITIONS OF FRESHALLY ISOLATED CELLS
PL2172211T3 (en) A composition of tumor associated peptides and associated cancer vaccine for the treatment of glioblastoma (GBM) and other types of cancer
IL243462A (en) Phosphate based oligomers and conjugates for delivering therapeutic agents into living cells and cell nuclei
IL244945A0 (en) Cationic lipid, lipid formulations including it and their use in the preparation of therapeutic agents for administration to cells
DK2114531T3 (en) Dot plugs and methods for administering therapeutic agents
EP2552439A4 (en) METHODS OF IMPROVING DRUG ADMINISTRATION AND THE EFFICIENCY OF THERAPEUTIC AGENTS
EP2356446A4 (en) DIAGNOSTIC AND THERAPEUTIC METHODS RELATING TO CANCER STEM CELLS
DK2297106T3 (en) PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN TREATMENT OF PDE4-MEDIATED DISEASES
EP2416652A4 (en) METHODS OF ADMINISTERING OLIGONUCLEOTIDES INTO DIRECTION OF IMMUNE CELLS
DK2016089T3 (en) GENE DEFECTS AND MUTANT-ALK-KINASE IN HUMAN FIXED TUMORS
WO2011069141A3 (en) Interferon therapies in combination with blockade of stat3 activation
DK3064579T3 (en) Pharmaceutical compositions and medicinal uses of engineered human arginases
EP2136846A4 (en) THERAPEUTIC TARGETS AND MOLECULES
EP2222344A4 (en) DENDRITIC CELL VACCINE COMPOSITIONS AND USES THEREOF
EP1986685A4 (en) COMPOSITIONS OF VACCINE DELIVERY MODES AND METHODS OF USE
EP2376089A4 (en) CANCER VACCINE COMPOSITIONS AND THEIR METHODS OF USE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090527

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100105

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100504

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140419